Supernus Pharmaceuticals | SUPN - Current Liabilities


Supernus Pharmaceuticals reported $338.17M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Abbott USD 16.5B 1.91B Dec/2025
ANI Pharmaceuticals USD 278.11M 7.56M Dec/2025
Aurora Cannabis CAD 145.94M 21.82M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Canopy Growth CAD 98.29M 17.19M Dec/2025
Cara Therapeutics USD 11.04M 362K Sep/2025
Corcept Therapeutics USD 166.08M 6.18M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Novo Nordisk DKK 215.66B 18.7B Dec/2025
Pacira USD 120.59M 13.51M Dec/2025
Perrigo USD 1.01B 132.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Supernus Pharmaceuticals USD 338.17M 7.54M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Xeris Pharmaceuticals USD 109.57M 6.63M Dec/2025